Trial Profile
A Multi-center, Multinational, Noninterventional Study With Certolizumab Pegol in Comparison to Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Adalimumab; Disease-modifying antirheumatics; Etanercept; Golimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms NexT
- Sponsors UCB Pharma SA
- 20 Jul 2020 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 23 Oct 2020 to 1 Aug 2020.
- 28 Feb 2019 Planned primary completion date changed from 23 Oct 2020 to 1 Aug 2020.